TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i> -Mutant Tumors to Anti–PD-1 Immunotherapy

Targeting CoREST with TNG260 sensitizes STK11-deficient non-small cell lung cancer to anti-PD-1 immunotherapy, offering a potential treatment for patients not served by existing therapies. See related commentary by Lin and Shen, p. 3821.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-08-29
DOI
https://doi.org/10.1158/0008-5472.can-25-0998
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Brian Doyon, Suleman S. Hussain, Jiehui Deng, Preksha Shahagadkar et al.
1 citations
Cancer Research
Cancer Immunotherapy and Biomarkers
1.05
article

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Brian Doyon, Suleman S. Hussain, Jiehui Deng, Preksha Shahagadkar, Alfonso Lopez, David R. Spigel, Hsin‐Jung Wu, Kwok‐Kin Wong, Minjie Zhang, Hideo Watanabe, Kenjie Amemiya, John P. Maxwell, Magdalena A. Ploszaj, Judy S. Wang, Ayushi S. Patel, Chengyin Min, Adam Crystal, Mary Meynardie, Jonathan Wade Goldman, Michela Ranieri, Heather DiBenedetto, Iga Sienczylo, Jannik N. Andersen, Douglas A. Whittington, Reshmee Bhattacharya, Alan Huang, Yi Yu, Alexander I. Spira, Ferdinandos Skoulidis, Soumyadip Sahu, Janaye Stephens, Leanne G. Ahronian, Alice Tsai, Patrick McCarren, David J. Guerin, Andre Mignault, Julie A. Shields, Lauren R. Flynn, Salman Rafi Punekar, Gerald S. Falchook, Yeuan Ting Lee, Nikitha M. Das, Yi Jer Tan, Jaylen M. Powell, Ke Geng, Samuel R. Meier, Jacques Ermolieff, Ting Chen, Brian J. McMillan, Xinyuan Wu, Brian B. Haines, Laney Danielczyk
article en
1 citations

Abstract

Targeting CoREST with TNG260 sensitizes STK11-deficient non-small cell lung cancer to anti-PD-1 immunotherapy, offering a potential treatment for patients not served by existing therapies. See related commentary by Lin and Shen, p. 3821.

Cancer ResearchVol. 85(20)
The University of Texas MD Anderson Cancer Center (US), University of California, Los Angeles (US), UCLA Health (US), NYU Langone Health (US), Tango Therapeutics (United States) (US), Hinge Health (US), Sarah Cannon (US), Jnana Therapeutics (United States) (US), Florida Cancer Specialists & Research Institute (US), HealthONE (US), Virginia Cancer Specialists (US), Tennessee Oncology (US), The US Oncology Network (US), Io Therapeutics (United States) (US), New York University (US), The University of Texas Southwestern Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Celgene, NYU Langone Medical Center, National Institutes of Health, Genentech, Foundation Medicine, National Cancer Institute, Janssen Pharmaceuticals
Openalex Percentile: Top 18%
Cancer Immunotherapy and Biomarkers
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.